RxDoctor Payments Data

Rashmi Halker Singh, MD

Neurology · Scottsdale, AZNPI 1508895582

Payments from drug & device makers

$82,114in general payments, 2019–2025

Across 53 payments — averaging $1549.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$30K
  • AbbVie$19K
  • Pfizer$12K
  • H. Lundbeck A S$12K
  • Teva Pharmaceuticals USA, Inc.$5K
  • Supernus Pharmaceuticals, Inc.$2K
  • plus $2K from 5 others

What the payments were for

  • Consulting fees$29,47373%
  • Speaking & faculty fees$6,70017%
  • Travel & lodging$2,3656%
  • Food & beverage$1,9805%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen4$29,929
AbbVie(2 entities)30$19,391
Pfizer7$12,053
H. Lundbeck A S1$11,610
Teva Pharmaceuticals USA, Inc.1$4,633
Supernus Pharmaceuticals, Inc.2$2,148
Lundbeck LLC3$1,706
Biogen1$400
Lilly USA, LLC2$119
Impel Pharmaceuticals Inc.1$111
Tonix Medicines, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,114 in reported general payments places this provider in the 80th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$89,110
Medicare patients
192
Services billed
8,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate23$45,965
Aimovig AutoinjectorErenumab-Aooe31$32,247
Emgality PenGalcanezumab-Gnlm35$31,939
UbrelvyUbrogepant28$30,487
QuliptaAtogepant18$22,573
Gabapentin23$870
Topiramate43$581
RizatriptanRizatriptan Benzoate36$438
Duloxetine Hcl13$368
Naratriptan Hcl12$154
Sumatriptan Succinate13$116
Zonisamide13$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$19,391$53,06046 claims
PfizerNurtec Odt$12,053$45,96523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 neurology providers in Arizona.

Other neurology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →